MARLBOROUGH, Mass. / Apr 03, 2023 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2023 on Monday, May 1, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
Interested participants may listen to the call by dialing (888) 600-4862 (in the United States and Canada) or +1 (773) 305-6865 (for international callers) and referencing access code 2312014. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. A webcast replay will be available approximately two hours after the call ends.
Hologic will provide a live and webcast replay of the call on the Company’s website at www.investors.hologic.com. The call will be available there for 30 days.
About Hologic
Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.
| Last Trade: | US$71.65 |
| Daily Change: | 0.89 1.26 |
| Daily Volume: | 7,640,910 |
| Market Cap: | US$16.260B |
December 18, 2024 December 09, 2024 December 02, 2024 November 04, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
